8-K: Verastem Oncology Announces Promising Initial Results for Pancreatic Cancer Treatment

Verastem Oncology reports positive initial safety and efficacy results from its RAMP 205 trial, showing an 83% partial response rate in a cohort of patients with metastatic pancreatic cancer.

Summary

• Verastem Oncology held its annual stockholder meeting on May 23, 2024, where directors were elected and proposals were voted on.
• The company announced initial interim results from the RAMP 205 trial, evaluating avutometinib and defactinib in combination with chemotherapy for first-line metastatic pancreatic cancer.
• As of May 14, 2024, 41 patients were treated across four dose cohorts.
• In the first dose cohort, 83% (5 out of 6) of patients achieved a confirmed partial response.
• 21 out of 26 patients who had a scan showed a reduction in tumor size.
• The median age of patients in the trial was 64 years, with 46% being male.
• 12 patients experienced 19 treatment-emergent serious adverse events, with 11 patients experiencing grade 3 events.
• The company will present these results at the ASCO Annual Meeting on June 1, 2024.
• Verastem will host an investor call on May 24, 2024, to discuss the data and the initiation of a rolling NDA submission for a different cancer.

Sentiment

Score: 8

Explanation: The document presents very positive initial results from a clinical trial, which is a significant positive for the company. However, there are also risks and uncertainties associated with drug development, so the sentiment is not a perfect 10.

Positives

• The 83% partial response rate in the first dose cohort is a very promising result for a difficult-to-treat cancer.
• The reduction in tumor size observed in 21 out of 26 patients is encouraging.
• The study is supported by a PanCAN Therapeutic Accelerator Award, highlighting its importance.
• The company is actively working to determine the optimal dose for Phase 2 expansion.
• The combination therapy targets a key pathway in pancreatic cancer, increasing its potential effectiveness.

Negatives

• One dose-limiting toxicity was observed in the first dose cohort, though the dose level was cleared after additional patients were evaluated.
• 12 patients experienced 19 treatment-emergent serious adverse events, including grade 3 events.
• Two patients discontinued treatment due to adverse events.

Risks

• The results are from an interim analysis and may change as the trial progresses.
• The study is still in the dose-finding phase, and the optimal dose is yet to be determined.
• There are risks associated with the development and commercialization of new drugs, including regulatory approvals and market acceptance.
• The company faces competition from other companies developing treatments for pancreatic cancer.
• The company may not have sufficient cash to fund its operations.

Future Outlook

The company plans to continue the RAMP 205 trial to determine the recommended Phase 2 dose and is also initiating a rolling NDA submission for a different cancer. They are also continuing to develop other drug candidates and combinations.

Management Comments

• John Hayslip, M.D., chief medical officer of Verastem Oncology, stated that the initial results are encouraging and demonstrate the importance of targeting the RAS/MAPK pathway.
• Anna Berkenblit, M.D., MMSc, Chief Scientific and Medical Officer at PanCAN, expressed hope that the results from this study lead to improved outcomes for patients with pancreatic cancer.

Industry Context

The announcement is significant as pancreatic cancer is a difficult-to-treat disease with a high mortality rate, and new treatment options are urgently needed. The focus on the RAS/MAPK pathway is relevant as it is a common mutation in pancreatic cancer. The results are being presented at a major oncology conference, ASCO, indicating the importance of the findings.

Comparison to Industry Standards

• The 83% partial response rate in the first cohort of the RAMP 205 trial is notably higher than the typical response rates seen with standard chemotherapy regimens for metastatic pancreatic cancer, which are often in the range of 20-30%.
• While direct comparisons are difficult without full trial data, the results appear to be competitive with other novel targeted therapies in development for pancreatic cancer, such as those targeting KRAS mutations directly.
• Companies like Mirati Therapeutics and Amgen are also developing KRAS inhibitors, and Verastem's approach of combining a RAF/MEK clamp with a FAK inhibitor could offer a different mechanism of action and potentially improved outcomes.
• The RAMP 205 trial is also supported by the PanCAN Therapeutic Accelerator Award, which is a significant endorsement of the potential of the treatment approach.

Stakeholder Impact

• Shareholders will likely react positively to the promising clinical trial results.
• Patients with metastatic pancreatic cancer may have a new treatment option in the future.
• Employees of Verastem Oncology may be motivated by the positive results.
• The company's partners and collaborators may see increased value in their relationships.

Next Steps

• The company will continue the RAMP 205 trial to determine the recommended Phase 2 dose.
• The company will present the initial results at the ASCO Annual Meeting on June 1, 2024.
• Verastem will host an investor conference call on May 24, 2024, to discuss the data and the initiation of a rolling NDA submission in recurrent KRAS mutant low-grade serous ovarian cancer.

Key Dates

Keywords

pancreatic cancer, avutometinib, defactinib, RAMP 205, clinical trial, metastatic cancer, chemotherapy, ASCO, RAS/MAPK pathway, KRAS mutation